Thyroid autoantibodies (anti-TPO) associated with subset of CSU
Mechanism unclear; euthyroid patients can still have reactive urticaria
Therapeutic Considerations
Antihistamine pharmacology
Second-generation H1 antihistamines are first-line
Minimal CNS penetration and sedation at standard doses
Inverse agonists at H1 receptor (not simply competitive antagonists)
Continuous dosing more effective than PRN use (NEJM 2022)
Dose escalation rationale
Up to 4x standard dose used in CSU (EAACI/GA2LEN/EDF/WAO guideline)
Higher H1 receptor occupancy achieved at supranormal doses
H2 receptor role
H2 receptors present on skin vasculature
Additive vasodilation blockade when H2 combined with H1 blockers
Omalizumab mechanism and evidence
Anti-IgE monoclonal antibody
Binds free IgE preventing mast cell and basophil activation
Reduces FcεRI receptor density on mast cells
JAMA 2024 (Kolkhir et al.): CSU comprehensive review
Omalizumab 300 mg q4 weeks most effective for refractory CSU
Class I recommendation for antihistamine-refractory CSU
Response assessment
Complete response in 40–60% of patients
Partial response in additional 20%
Non-responders may have HAE overlap or alternative diagnosis
Corticosteroid limitations
Short courses acceptable for acute refractory urticaria
Prednisone 40–50 mg for 3–5 days (evidence conflicting per ACEP)
RCT (American Journal of Emergency Medicine 2021) did not show benefit of adding IV corticosteroids to antihistamines in acute urticaria
Long-term use contraindicated in chronic urticaria
Adrenal suppression, metabolic consequences
AFP guideline recommendation
Natural history and prognosis
Acute urticaria: most cases resolve within days to weeks
Spontaneous resolution without specific trigger identified in majority
Chronic urticaria remission rates
Approximately 50% achieve remission within 1–5 years (NEJM 2022)
Disease may wax and wane over years
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for Urticaria (Hives)
What you have been diagnosed with
Urticaria (hives) is a skin condition causing raised, itchy, red welts
Individual welts usually disappear within 24 hours but new ones may appear
Most cases of acute hives are temporary and resolve on their own within days to weeks
Your medications
Take your antihistamine tablet every day as prescribed, not just when hives appear
Taking it daily gives better control than waiting until symptoms start
If you were given a steroid tablet (prednisone), take it with food and complete the full course
What to avoid
Avoid ibuprofen, naproxen, aspirin, and other NSAID pain relievers — use acetaminophen (Tylenol) instead
Avoid alcohol (may worsen hives)
Avoid tight-fitting clothing and excessive heat
Avoid any food or substance you suspect triggered this episode
Follow-up instructions
See your family doctor within 1–2 weeks if hives persist
If you have had hives for more than 6 weeks, a more detailed allergy workup is needed
If you received an epinephrine auto-injector prescription, fill it today and carry it at all times
Photograph your skin lesions on your phone when they appear — they may be gone by the time you see a doctor
Return to the emergency department immediately if you experience
Difficulty breathing, wheezing, or throat tightness
Swelling of the tongue, lips, or throat
Feeling faint, dizzy, or losing consciousness
Chest pain or rapid heartbeat with hives
Abdominal pain, vomiting, or diarrhea with hives
Hives that rapidly spread despite antihistamines
Worsening hives after epinephrine auto-injector use (call 911)
Additional patient counseling
Hives often have no identified cause and are not dangerous on their own
Chronic hives (greater than 6 weeks) can be well-controlled with daily antihistamines and specialist care
Stress can trigger or worsen hives in some people — stress management may help
References
Guidelines and key sources
Primary clinical guidelines
Semenya AM, Pienkowski S, Bhatnagar P. Acute and Chronic Urticaria: Evaluation and Treatment. American Family Physician. 2026.
Primary clinical management reference for this document
PMID 41839072
Zuberbier T, et al. EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. Allergy. 2018.
International consensus guideline
Dose escalation of H1 antihistamines and omalizumab recommendation
Bernstein JA, Lang DM, Khan DA, et al. The Diagnosis and Management of Acute and Chronic Urticaria: 2014 Update. Journal of Allergy and Clinical Immunology. 2014.
US-focused management guideline
Key review articles
Kolkhir P, Bonnekoh H, Metz M, Maurer M. Chronic Spontaneous Urticaria: A Review. JAMA. 2024.
Comprehensive CSU review including omalizumab evidence
Lang DM. Chronic Urticaria. New England Journal of Medicine. 2022.
Marzano AV, et al. Urticarial Vasculitis. Journal of Allergy and Clinical Immunology. 2022.
Differential diagnosis and biopsy criteria
Pediatric and special population references
Bezirganoglu H, et al. The common triggers of urticaria in children admitted to the pediatric emergency room. Pediatric Dermatology. 2022.
Pediatric trigger data and beta-lactam association
Foley G. Urticaria. Clinical Guide to Paediatrics. 2022.
Pediatric clinical framework
Trial and epidemiology data
Palungwachira P, et al. A Randomized Controlled Trial of Adding Intravenous Corticosteroids to H1 Antihistamines in Patients With Acute Urticaria. American Journal of Emergency Medicine. 2021.
IV corticosteroid adjunct RCT; no significant benefit demonstrated
Tan S, Chen Z, Lin T. Global, Regional, and National Burden of Urticaria (1990-2021). BMC Public Health. 2025.
Epidemiologic burden data and risk factors
Jamjanya S, et al. Evaluation of Pharmacological Treatments for Acute Urticaria: Systematic Review and Meta-Analysis. Journal of Allergy and Clinical Immunology In Practice. 2024.
Comparative pharmacotherapy evidence
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.